Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
230.6 USD | +4.78% | +9.09% | -0.37% |
Financials (USD)
Sales 2024 * | 75.76M | Sales 2025 * | 361M | Capitalization | 4.69B |
---|---|---|---|---|---|
Net income 2024 * | -583M | Net income 2025 * | -403M | EV / Sales 2024 * | 52.8 x |
Net cash position 2024 * | 694M | Net cash position 2025 * | 292M | EV / Sales 2025 * | 12.2 x |
P/E ratio 2024 * |
-7.77
x | P/E ratio 2025 * |
-12.1
x | Employees | 376 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.63% |
Latest transcript on Madrigal Pharmaceuticals, Inc.
1 day | +1.33% | ||
1 week | +7.22% | ||
Current month | +7.86% | ||
1 month | +3.78% | ||
3 months | -5.61% | ||
6 months | +24.57% | ||
Current year | -4.89% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Craves
FOU | Founder | 78 | 11-08-31 |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 230 | +4.54% | 144 054 |
24-05-17 | 220.1 | +1.33% | 236,438 |
24-05-16 | 217.2 | +2.57% | 235,183 |
24-05-15 | 211.7 | +0.36% | 392,484 |
24-05-14 | 211 | -0.16% | 262,278 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.89% | 4.69B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- MDGL Stock